Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) provides access to the company’s official regulatory disclosures as a clinical-stage TechBio and biotechnology issuer. These documents offer detailed information about Recursion’s financial condition, governance, capital markets activity and key corporate events related to its Recursion OS platform and drug development programs.
Investors can review current reports on Form 8-K, where Recursion reports material events such as quarterly financial results, leadership transitions, collaboration milestones and equity issuances. Recent 8-K filings describe items including second and third quarter financial results, the appointment of a new Chief Executive Officer and President with the prior CEO becoming Chair of the Board, milestone payments from collaborations, and unregistered sales of equity securities connected to acquisitions and license arrangements.
Through its registration statements and prospectus supplements filed under its automatic shelf registration on Form S-3ASR, Recursion documents offerings and resale registrations for shares issued in connection with agreements such as a master license with Tempus AI, Inc. and a membership interest purchase agreement involving a joint venture for an ENPP1 program. These filings outline the number of shares involved, transaction structure and reliance on exemptions from registration for initial issuances.
Users of this page can also monitor filings related to corporate governance and stockholder matters, such as annual meeting results and advisory votes, as well as information about independent auditor ratification. Together with annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible through EDGAR, these filings form a comprehensive record of RXRX’s regulatory history.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of key filings. This helps readers quickly interpret lengthy documents such as 10-K and 10-Q reports, understand the implications of Form 8-K disclosures, and track any insider-related or equity issuance activity that may be relevant when evaluating Recursion Pharmaceuticals.
Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Zavain Dar received a grant of 4,902 shares of Class A Common Stock. The shares were issued at no cash cost to him under the company’s Outside Director Compensation Policy and are reported as directly owned. Following this award, he holds 147,231 Class A shares.
Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Dean Y. Li received a grant of 3,268 shares of Class A Common Stock at $0.0000 per share. The shares were issued under the company’s Outside Director Compensation Policy, reflecting equity-based compensation rather than an open-market purchase.
Following this grant, Li directly owns 1,244,177 Class A shares. He also has indirect ownership through several entities, including the Dean Y. Li Revocable Trust, the Dean Y. Li GRAT, and the Dean Y. Li 2021 Family Trust, each with separately reported share balances.
Recursion Pharmaceuticals Inc filing: The Vanguard Group amended its Schedule 13G/A to report that it beneficially owns 0 shares of Recursion Pharmaceuticals Inc common stock, representing 0% of the class. The filing explains this follows an internal realignment of The Vanguard Group, Inc., resulting in disaggregated reporting by subsidiaries.
Recursion Pharmaceuticals is changing its top medical leadership. Vicki Goodman, M.D. will become Chief Medical Officer effective April 6, 2026, succeeding David Mauro, M.D., Ph.D., who will stay on as an advisor through May 29, 2026.
The company highlights Dr. Goodman’s more than two decades of oncology drug development experience, including senior roles at biotech and large pharmaceutical companies and prior service as an FDA medical officer. Management emphasizes her expertise in late-stage clinical development and regulatory strategy as Recursion advances its pipeline toward key clinical and regulatory milestones.
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock. He converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold 40,000 Class A shares at $3.25 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan. Following these transactions, he holds 906,556 shares of Class A Common Stock and 4,483,334 shares of Class B Common Stock directly.
RXRX filed a Form 144 reporting proposed sales of Class A founder shares.
The filing lists four sales of 40,000 Class A shares on 01/05/2026, 01/20/2026, 02/04/2026, and 02/19/2026 with proceeds of $170,000, $178,800, $164,800, and $138,400, respectively.
Recursion Pharmaceuticals Chief Financial Officer Ben R. Taylor reported routine share movements in company stock. On March 17, 2026, he completed an open-market sale of 7,956 shares of Class A Common Stock at $3.39 per share. On March 16, 2026, 7,075 shares were disposed to cover tax obligations tied to net settlement of restricted stock units, which is not an open-market trade. After these transactions, Taylor directly held 1,180,318 shares of Class A Common Stock. The open-market sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025, indicating the timing was planned in advance.
RXRX submitted a Form 144 reporting the proposed sale of 7,956 Class A shares tied to restricted stock vesting on 03/15/2026. The filing lists prior dispositions by Ben Taylor of 21,383 Class A shares on 12/29/2025 and 13,426 Class A shares on 02/18/2026. The broker listed is Fidelity Brokerage Services LLC.
Recursion Pharmaceuticals director Christopher Gibson converted 20,000 shares of Class B Common Stock into 20,000 shares of Class A Common Stock on March 9, 2026. The conversion price was reported as $0.00 per share.
On the same date, he made a bona fide gift of 20,000 Class A shares, leaving him with 906,556 Class A shares directly owned and 4,523,334 Class B shares directly owned after these transactions.
RECURSION PHARMACEUTICALS, INC. CEO and President Najat Khan reported an open-market sale of 28,298 shares of Class A common stock on March 9, 2026 at a weighted average price of $3.3451 per share. The trades were executed at prices ranging from $3.32 to $3.405.
After this transaction, Khan directly holds 2,262,085 shares of Class A common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, indicating the timing was set in advance rather than decided opportunistically.